ERBB2 and breast cancer: Brain metastases of breast cancer, mostly in patients with HER2+ or triple-negative tumors, have exceeded the incident rate of 30% in metastatic breast cancer patients [31] and confer a poor prognosis, with extremely short survival despite treatment [32].